1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
PRISM BioLab Co. LTD

PRISM BioLab Co. LTD

TTSE:206A
132.00
JPY
-4.00
(-2.94%)
6.62BMarket Cap
Nov 13Next Earn
PRISM BioLab Co. LTD
TSE:206A
(Tokyo Stock Exchange)

Recent

price

132.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
JPY
18.6
3.79
9.76
18.54
- -
Revenue per Share
2.45
-17.68
-33.53
-22.82
- -
Basic EPS, GAAP
3.26
-18.4
-1.97
-42.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
47.37
32.47
97.43
73.59
57.62
Book Value per Share
47.37
32.47
97.43
73.59
57.62
Tangible Book Value per Share
30
30
31
37
37
Basic Weighted Avg Shares
554
113
306
677
- -
Sales/Revenue/Turnover
12.03
-440
-256
-114.34
- -
Operating Margin (%)
1
9
- -
- -
- -
Depreciation Expense
73
-527
-1,050
-834
- -
Net Income, GAAP
1.61
- -
- -
- -
- -
Effective Tax Rate (%)
13.16
-466.6
-343.4
-123.09
- -
Profit Margin (%)
1,667
1,134
3,463
2,669
2,091
Working Capital
- -
- -
- -
- -
- -
LT Debt
1,675
1,148
3,503
2,709
2,130
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-37.33
-45.13
-26.84
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
6,184
5,762
6,617

Working Capital

JPY

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
3,039
- -
2,541
Cash, Cash Equivalents & STI
2,916
- -
2,454
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
370
- -
450
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-22.67%
Free Cash Flow
- -
- -
2,395.49%
Net Income, GAAP
- -
- -
-20.56%
Sales/Revenue/Turnover
- -
- -
121.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
306
2025
- -
- -
- -
- -
677
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-33.53
2025
- -
- -
- -
- -
-22.82
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
PRISM BioLab Co., Ltd. (206A.T) develops small molecule inhibitors targeting protein-protein interactions using its proprietary PepMetics technology platform, which generates orally available compounds mimicking alpha-helix and beta-turn peptides to address undruggable targets in oncology, autoimmune diseases, fibrosis, and other indications; the PepMetics library comprises over 20,000 compounds for screening difficult therapeutic areas. Core pipeline assets include E7386, a CBP/beta-catenin inhibitor co-developed with Eisai Co., Ltd. in Phase II trials for cancer, and PRI-724, also targeting CBP/beta-catenin, advancing in Phase II for cirrhosis under license to Ohara Pharmaceutical Co., Ltd., alongside seed compounds for novel bicyclic PepMetics. Founded in 2006 and headquartered in Fujisawa, Japan, with a Tokyo office, the company operates primarily in Japan and pursues global collaborations. Recent developments encompass achievement of an initial milestone and receipt of upfront payment from Ono Pharmaceutical Co., Ltd. in a November 2025 drug discovery alliance for oncology targets; a new April 2025 partnership with Elix, Inc. to integrate AI-driven design into PepMetics research; patent grants in 2025 for novel bicyclic PepMetics compounds and library technologies; initiation of patient enrollment in a Phase I drug-drug interaction study for PRI-724; terminations of prior collaborations with Servier and Eli Lilly in 2025; a 1.5 billion yen Series C funding round in January 2024; and recruitment of key scientific talent in 2025 to bolster medicinal chemistry and translational pharmacology capabilities.